Drug intelligence / Profile preview

allogeneic umbilical cord-derived mesenchymal stromal cells (Institute of Oncology Ljubljana)

Development stage
Unknown
Lead developer
Institute of Oncology Ljubljana
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intraglandular Injection
01

Overview

This investigational cell therapy, developed by the Institute of Oncology Ljubljana, utilizes allogeneic mesenchymal stromal cells (MSCs) derived from umbilical cord tissue for the treatment of radiation-induced xerostomia. Targeted at patients with head and neck cancer who have suffered salivary gland damage following radiotherapy, the MSCs are administered via ultrasound-guided injection directly into the parotid or submandibular glands. The therapy aims to restore salivary function by leveraging the MSCs' innate immunomodulatory, anti-inflammatory, and regenerative properties to repair damaged glandular tissue. It is currently being evaluated in a Phase I pilot clinical trial to determine safety and preliminary efficacy in patients who have been disease-free for at least two years post-treatment.

Other names
Allogeneic Mesenchymal Stromal CellsAllogeneic Mesenchymal Stromal Stem CellsAllogeneic MSCs

Beyond the preview

Go deeper on allogeneic umbilical cord-derived mesenchymal stromal cells (Institute of Oncology Ljubljana).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stromal cells (Institute of Oncology Ljubljana).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call